STAREE — the first big primary-prevention statin trial in older adults — found atorvastatin reduced cardiovascular events, though it didn’t extend disability-free survival.
In a small study where researchers supplied every meal, a ketogenic diet reduced liver fat more than Mediterranean or low-fat diets — even though all three produced similar weight loss.
The bictegravir/lenacapavir tablet gives virologically suppressed adults — including those on complex regimens — a new one-pill, once-a-day option.
The WEE1 inhibitor APR-1051 shrank tumors in some patients with gynecologic cancers in an early trial, prompting Aprea to expand testing.
Removing a protein called AHR let injured neurons switch into repair mode, improving recovery of movement and sensation in mice — and drugs that block it are already in trials for other uses.
Spanish researchers built molecules that switch on in light and stand in for lost photoreceptors, reawakening the retina’s surviving circuitry in animals blinded by degeneration.
By flipping a Notch-signaling switch, researchers grew functional helper T cells from stem cells at scale — a step toward ready-made cell therapies that skip per-patient manufacturing.
Rusfertide mimics the body’s iron-regulating hormone to rein in red-blood-cell overproduction — and in a trial, most patients no longer needed regular blood draws.
The FDA expanded tirzepatide’s label to include cutting cardiovascular risk in type 2 diabetes — a first for a GIP/GLP-1 drug and a boost for the world’s top-selling medicine.
Refreshed shots from Pfizer, Moderna and Novavax are updated for the now-dominant XFG strain — but this season’s approvals come with narrower eligibility than in past years.
Michael Polansky’s Outer Bio launched with $23M and an unusual pitch: not a drug company, but an AI platform screening compounds on living human skin.
Sequencing eight Myotis bat species uncovered genetic tricks linking their famous virus tolerance to cancer resistance and longevity — clues that could inform human aging research.